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Abstract
In Africa, human cytomegalovirus (CMV) is an important pathogen in a diverse range of patient groups. Congenital CMV
infection is common, and most children undergo primary infection during the first year of life. Preliminary studies suggest
that these early primary CMV infections could have population-wide effects on growth and development. In most studies
of adults, CMV seroprevalence is close to 100%, but some studies have found that significant minorities of adults are
seronegative. CMV is a common cause of pneumonia and meningitis in hospitalised immunosuppressed patient groups,
and CMV DNAemia may be an important marker of rapid progression and poor outcomes of HIV infection, despite roll-out
of antiretroviral therapy (ART). Diagnosis and treatment of CMV-related disease is broadly neglected in Africa, and no
randomised clinical trials of anti-CMV drugs have been conducted to date. Autopsy is rarely performed in Africa, but
identifies CMV as a frequent pathogen when it is carried out. Here we review the available literature on CMV in Africa,
primarily in adult patients, and discuss this in the context of contemporary understanding of CMV as a human pathogen.
Introduction
There is growing awareness of the possible importance of human
cytomegalovirus (CMV) as a cause or contributory factor in a range
of disease conditions in Africa and other developing regions
globally. In children, CMV is a common congenital infection the
outcomes of which are largely undefined in African populations
[1–3]. CMV is also an important cause of pneumonia [4–6] and
meningitis [7,8], strongly associated with HIV infection and
exposure, and is independently associated with impaired physical
development [7,9]. CMV is an important co-infection in HIV-
infected adult patient groups, and is associated with increased
morbidity and mortality [10,11], yet diagnosis and treatment are
broadly unavailable outside selected centres of excellence.
CMV infection in Africa has been overlooked for several reasons.
First, there is the perception that most Africans are universally
infected with CMV during childhood, and that maternal reactivation
or reinfection during pregnancy is less likely than primary infection
to cause severe congenital infection [12–14]. However, even in
high-income populations, the majority of congenital CMV
infections are the result of maternal reactivation or re-infection
[15]. Ignoring congenital CMV infection in Africa is therefore
shortsighted, and does not consider the possible confounding
effects of HIV infection, malnutrition, tuberculosis, and a general
higher disease burden. Secondly, CMV disease is an AIDS-defining
opportunistic infection [16]. With the roll-out of ART across Africa,
it has been assumed that the burden of disease caused by CMV
is small and getting smaller [10], and as a result CMV diagnostics
and treatment are broadly unavailable outside selected centres
of excellence [2,4–6]. Thirdly, there is an assumption that patients
in Africa do not receive immunosuppressive therapy that may cause
CMV disease, an increasingly obsolete view as access to more
advanced treatments and therapies for non-communicable diseases
as well as organ transplantation become more available [17,18].
In this review we summarise available data on CMV infections in
Africa, from the vast literature of CMV pathogenicity, immunology,
diagnosis and treatment available from studies undertaken in
high-income countries.
Seroprevalence
As for all herpesviruses, the natural host immune response to primary
CMV infection does not clear the virus completely, and it persists
in a latent or ‘non-lytic’ state [19]. In lower-income settings, primary
infection with CMV generally occurs earlier [9,20–22] than in
higher-income settings [23] (although this is not universally true,
as high prevalence of CMV IgG has been reported in studies from
Finland and Japan [24–26]). Data from the United States have
suggested that non-white ethnicity and lower socioeconomic status
could be responsible for a 10–30% increase in CMV seroprevalence
[27], although ethnic differences should be interpreted with caution:
there are no race-associated host genetic polymorphisms known
to be linked with earlier acquisition of CMV. Social and
environmental factors are the most probable determinants of age
of acquisition, and even when seroprevalence differences by
ethnicity hold when adjusting for socioeconomic status, such as
in an Israeli study [28], it could be socioeconomic status during
childhood that is important. For instance, migrants who spent their
childhood in sub-Saharan Africa might be more likely to be CMV
IgG seropositive, even if social mobility facilitated a rise in
socioeconomic status after settling in Israel.
We searched PubMed and identified 33 studies that present CMV
seroprevalence data from healthy blood donors and patient groups
in Africa (Table 1). The pooled prevalence of CMV IgG among
HIV-negative adults was 81.8% (range 55–97%). For HIV-infected
adults the pooled CMV IgG seroprevalence was lower among those
with clinically defined AIDS (81.9%, range 59–100%) than among
asymptomatic HIV-infected adults (94.8%, range 71–100%),
consistent with the notion of weaker humoral responses associated
with AIDS progression [29]. It is also possible that some non-HIV-
infected adults are infected but do not mount a measurable IgG
response. Among pregnant women seroprevalence mirrored that
among healthy blood donors, although the HIV status of
participants was not always stated (Table 1).
The number of children screened for CMV IgG was an order of
magnitude less than for adults, but pooled seroprevalence was
88.1% (range 80–100%). With this very high seroprevalence in
children (Table 1), even in very young infants [9], one would expect
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Table 1. Comparison of human CMV seroprevalence in different countries in Africa
Country (City) HCMV IgG Study population N Assay Reference
HIV-negative adults 81.8%
Nigeria (Ibadan) 55.0% Adult healthy blood donors 110 Complement fixation [30]
Mali (Bamako) 58.0% Adult healthy HIV-negative blood donors 100 ELISA (Platelia, Sanofi Pasteur) [31]
Tanzania (Dar es Salaam) 66.9% Adult inpatients with STDs (HIV-negative) 158 Passive latex agglutination (CMV-scan
card)
[32]
Ghana (Accra) 77.6% Adult healthy HIV-negative blood donors 3275 ELISA IgG (Diamedix Corporation, USA) [33]
Burkina Faso (Bobo-
Dioulasso)
82.0% Adult healthy HIV-negative blood donors 28 ELISA (Platelia, Sanofi Pasteur) [34]
Ghana (Kumasi) 94.3% Healthy blood donors 112 Platella CMV IgG (Bio-Rad) [35]
Somalia (Mogadishu) 96.0% Healthy adult males 102 Unspecified [36]
Somalia (Mogadishu) 96.0% Adult males attending STD clinic 101 Unspecified [36]
Kenya (Nairobi) 97.0% Adult healthy blood donors (1.3% HIV-
positive)
400 Unspecified [37]
Tunisia (Tunis) 89.0% Healthy adults 100 CMV IgG CMIA (Abbott Diagnostics) [38]
Kenya 97.0% Adult healthy blood donors 395 Not available [37]
Tunisia (Sfax) 97.0% Adult healthy blood donors 280 Enzygnost anti-CMV/IgG (Behring) [39]
HIV-positive adults 94.8%
Mali (Bamako) 71.0% HIV-positive adults 100 ELISA (Platelia, Sanofi Pasteur) [31]
Tanzania (Dar es Salaam) 72.3% Adult inpatients with STDs (HIV-positive) 65 Passive latex agglutination (CMV-scan
card)
[32]
Ghana (Kumasi) 92.7% Asymptomatic HIV-positive adults 55 Platella CMV IgG (Bio-Rad) [35]
Botswana (Gaborone) 95.3% Asymptomatic HIV-positive adults 43 [40]
South Africa (Mopani
District, Limpopo)
100.0% HIV-positive adults, ART naïve, mean CD4
cell count 382±226 cells/μL
405 Serion ELISA classic tests (Virion Serion) [41]
Tanzania (Mbulu) 100.0% HIV-positive adults, ART naïve, median
baseline CD4 cell count 205 (IQR 79–403)
cells/μL
168 CMV IgG CMIA (Abbott Diagnostics) [42]
Lesotho 100.0% HIV-positive, on ART 205 CMV IgG CMIA (Abbott Diagnostics) [43]
Nigeria (Ilorin) 93.9% Asymptomatic HIV-positive adults 180 IgG ELISA Kit (DIA.PRO, Diagnostic
Bioprobes, Italy)
[44]
AIDS patients 81.9%
Ghana (Accra) 59.2% AIDS patients 250 ELISA IgG; Diamedix Corporation, USA [33]
Mali (Bamako) 89.0% AIDS patients 100 ELISA (Platelia, Sanofi Pasteur) [31]
Tanzania (Dar es Salaam) 90.7% AIDS patients 43 Passive latex agglutination (CMV-scan
card)
[32]
Ghana (Kumasi) 98.3% AIDS patients 239 Platella CMV IgG (Bio-Rad) [35]
Burkina Faso (Bobo-
Dioulasso)
100.0% AIDS patients 36 ELISA (Platelia, Sanofi Pasteur) [34]
Pregnant women 87.8%
Tanzania (Dar es Salaam) 60.6% HIV-negative pregnant women 127 Passive latex agglutination (CMV-scan
card)
[32]
Tanzania (Dar es Salaam) 85.7% HIV-positive pregnant women 14 Passive latex agglutination (CMV-scan
card)
[32]
Benin (Cotonou) 97.2% Pregnant women 211 ETI-CYTOK-G PLUS ELISA (DiaSorin) [45]
Nigeria (Ibadan) 100.0% Pregnant and non-pregnant women 80 Peroxidase enzyme-labelled antigen (ELA) [46]
Nigeria (Kano) 91.1% Pregnant women 180 CMV IgG ELISA kit (Dialab, Austria) [47]
South Africa
(Johannesburg)
86.4% Pregnant women 2160 ELISA (M A Bioproducts, Virginia) [48]
Tunisia 80.9% Pregnant women 404 CMV IgG CMIA (Abbott Diagnostics) [49]
Sudan 72.0% Pregnant women 231 DRG Cytomegalie Virus (CMV) IgG Enzyme
Immunoassay Kit
[50]
The Gambia (Sukuta) 100.0% Pregnant women 169 ETI-CYTOK-G PLUS ELISA (DiaSorin) [51]
Kenya (Thika) 77.3% Pregnant women 260 CMV serum immunoglobulin G antibody
using a commercial enzyme-linked
immunosorbent assay (Wampole;
Inverness Medical Professional
Diagnostics)
[52]
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seroprevalence among adults to be consistently close to 100%.
It is therefore surprising that a significant minority of adults in
many studies are CMV IgG negative. Our pooled analysis of CMV
IgG seroprevalence is limited by the lack of data on confounding
variables and the use of different CMV IgG assays in different
studies, but CMV IgG is considered to be a readily detectable
biomarker, with many of the assays cited used routinely in the
transplant setting to define the CMV exposure of donor and
recipient. As detection of pathogen-specific IgG is the very
backbone of diagnostic programmes for HIV, malaria and many
other common infections, it seems unlikely, with the exception
of HIV-infected individuals, that the reason is impaired humoral
response to CMV, which is known for high immunogenicity.
Therefore, it cannot be excluded that seronegative adults are
protected from CMV infection in some unknown way. Possible
explanations include socioeconomic and host genetic factors.
Studying the host genetics of CMV-seronegative African adults
may identify novel markers of protection. Recently, Japanese
researchers found that the polymorphism Thr72Ala in NKG2D, a
leptin-like receptor expressed by NK cells, might be associated
with symptomatic congenital CMV infection [63]. Host
polymorphisms in mice have also been associated with differential
pathogenicity to HSV-1 [64], but there is currently no evidence
of a host polymorphism in humans that results in a sufficiently
rapid innate immune response that prevents establishment of
humoral immunity to herpesviruses.
CMV infections in African children
A detailed discussion of this topic is planned for a later issue of
the Journal of Virus Eradication. For this reason, we only summarise
here. CMV is important in African children for two reasons. First,
congenital CMV infection appears to be highly prevalent [65–67]
despite pre-existing maternal immunity, and is strongly associated
with maternal HIV infection [68]. The longitudinal outcomes of
congenital CMV infection (cCMV) in Africa have not been
thoroughly studied, but cases of sensorineural hearing loss and
sudden infant death have been documented [56]. There is an
emerging consensus that cCMV, along with other congenital and
neonatal infections, is an under-appreciated cause of morbidity
and mortality in African children [69]. Secondly, most African
children are infected with CMV early in infancy irrespective of HIV
infection or exposure [5,9,70,71], which is distinctly different from
higher-income settings where primary infection with CMV generally
occurs much later. Traditionally cCMV has been defined as
detection of CMV within 3 weeks postpartum, but in Africa many
infants undergo non-congenital primary CMV infection soon after
this cut-off [5], and preliminary studies suggest these early infant
Table 1. Continued
Country (City) HCMV IgG Study population N Assay Reference
Benin (Tanguiéta) 100.0% Pregnant women 283 ETI-CYTOK-G PLUS ELISA (DiaSorin) [53]
Egypt (Ismailia) 100.0% Pregnant women 546 CMV IgG (DIA.PRO Diagnostic Bioprobes,
Italy)
[54]
Children 88.1%
Cameroon (Kumba City) 88.5% Healthy children 4–6 years ~100 ELISA (unspecified) [55]
Cameroon (Kumba City) 98.0% Healthy children 11–14 years ~100 ELISA (unspecified) [55]
Gambia (Banjul) 86.4% Healthy children 12 months 178 Immunofluorescence? [56]
Gambia (Banjul) 80.4% Healthy children 138 ETI-CYTOK-G PLUS ELISA (DiaSorin) [57]
Mozambique (SE Transvaal) 88.0% Refugee children under 5 years ~100 ELISA (unspecified) [58]
Mozambique (SE Transvaal) 96.4% Refugee children under 11 years ~100 ELISA (unspecified) [58]
Nigeria (Ibadan) 100.0% Newborn infants 21 Peroxidase enzyme-labelled antigen (ELA) [46]
Zambia (Lusaka) 83.0% Healthy 18-month-old infants 460 ETI-CYTOK-G PLUS ELISA (DiaSorin) [9]
Kenya (Nairobi) 100.0% HIV-1-infected street children 71 ELISA kit (Murex) [59]
Egypt 100.0% Acute lymphoblastic leukaemia 68 ELISA kit (Diagnostic Systems
Laboratories, Inc., USA)
[60]
Tuberculosis studies 83.0%
Nigeria (Ibadan) 50.6% Non-TB 89 Complement fixation [30]
Nigeria (Ibadan) 87.6% Tuberculosis patients 161 Complement fixation [30]
Burkina Faso (Bobo-
Dioulasso)
95.0% TB-positive, HIV-positive 40 ELISA (Platelia, Sanofi Pasteur) [34]
Burkina Faso (Bobo-
Dioulasso)
96.5% Tuberculosis patients 80 ELISA (Platelia, Sanofi Pasteur) [34]
Burkina Faso (Bobo-
Dioulasso)
97.5% TB-positive, HIV-negative 40 ELISA (Platelia, Sanofi Pasteur) [34]
Other 94.5%
Eritrea (various locations) 94.8% Various 439 ELISA (unspecified) [61]
Burundi (Bujumbura) 99.0% Ophthalmic patients 154 ELISA Enzygnost CMV (Abbott
Laboratories, USA)
[62]
Tunisia 94.9% HIV-negative adults with
haemoglobinopathies
59 CMV IgG CMIA (Abbott Diagnostics) [38]
Tunisia 77.0% HIV-negative children with thalassemia or
haemophilia
48 CMV IgG CMIA (Abbott Diagnostics) [38]
Adapted from [2]. Percentages in bold are the averages within each group, weighted by study size. CMIA, chemiluminescent microparticle immunoassay
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non-congenital infections could also be associated with
developmental sequelae. CMV shedding in African infants is
associated with vertical transmission of HIV [71], and these early
infant non-congenital CMV infections are independently associated
with impaired physical development, and among HIV-exposed
children, impaired psychomotor development [9]. CMV pneumonia
is the most prevalent acute disease presentation [72], strongly
associated with HIV infection [4–6]. CMV is also a probable cause
of meningitis and gastrointestinal infection in African children, with
or without accompanying bacterial infection [7,73], but routine
diagnosis and treatment is broadly unavailable.
CMV and HIV-infected African adults
Before effective antiretroviral therapy was available, CMV end-
organ disease was a common complication of HIV infection in
industrialised countries, mainly occurring in patients with CD4 T
cell counts <50 cells/μL [74]. However, after introduction of
combination ART, CMV disease became a rare complication in this
setting [75]. In Africa, access to ART is improving [76], but
HIV-associated tuberculosis and bacterial pneumonia continue to
be leading causes of death [72,77]. The role of CMV comorbidity
in these patient groups is largely unknown, as diagnostic testing
for CMV is not routinely performed.
CMV retinitis
Retinitis is the most common manifestation of CMV disease in
HIV-infected patients in Western countries [78], and this has led
to a body of work investigating CMV retinitis in developing
countries. In a systematic review of HIV-infected individuals in in
Africa (18 studies, 4325 patients), the prevalence of CMV retinitis
was 2.2% (95% CI: 1.3–3.1%), significantly lower than in Asia [79].
One reason for this difference may be lower CD4 T cell counts
on starting ART in Asia compared to Africa [80]. However, a study
comparing the prevalence of CMV retinitis in India and South Africa
found retinitis to be significantly less common in South Africa,
even after controlling for differences in ART use [81]. In Africa,
widespread pre-existing CMV immunity from infancy may
contribute to different prevalence of CMV retinitis in African adults
compared to adults coming from lower CMV seroprevalence
settings. It is unknown whether there are any genetic factors that
might influence different levels of CMV retinitis between African
and Asian populations.
CMV extraocular disease and autopsy
In contrast to CMV retinitis, which can be diagnosed by
ophthalmoscopy, confirmatory diagnosis of extraocular CMV
disease generally requires histopathological examination of biopsy
or post mortem specimens, procedures that are not widely available
in Africa. Whilst molecular diagnostic tests to detect CMV DNA
are now commonly used in the research setting [6,7,42], detection
of DNA in most clinical specimens does not automatically indicate
disease and need for treatment and there is still insufficient data
to define reliable viral load cut-offs for most patient groups [5].
Several research studies from Africa indicate that CMV may be
an important pathogen in patients with suspected acute
neurological disease. A study of meningitis in an HIV-Infected
Ugandan cohort detected CMV in the cerebrospinal fluid (CSF)
in 7% of patients, frequently in combination with other pathogens
[82]. In Malawi, CMV was detected in the CSF in 14% (2/14) of
HIV-infected patients with aseptic meningitis [83]. In this study,
confirmed bacterial or fungal meningitis cases were not screened
for viruses, but a later study from the same research group, found
CMV in the CSF of 10% (11/115) of HIV-infected patients with
bacterial meningitis [8]. This study also showed a significant
association between dual EBV/CMV infection and mortality, with
dual herpesvirus infection possibly eliciting greater CSF
inflammation than mono-infection. A study from a tertiary care
centre in Zambia found CMV in the CSF of 6% of HIV-infected
adults with symptoms suggestive of CNS opportunistic disease,
frequently in combination with other pathogens [84]. Together,
these four studies indicate that CMV is detectable in the CSF of
a minority of HIV-infected individuals with suspected meningitis
or CNS opportunistic disease, and is associated with poor outcome.
In resource-rich settings, CMV is not generally recognised as a
cause of isolated meningitis in HIV-infected adults, but is
established as a cause of encephalitis, myelitis, polyradiculopathy
and peripheral neuropathy. However, the above studies do not
reveal sufficient data to conclude whether detection of CMV DNA
in the CSF is a feature of any of these diverse neurological
manifestations. Imaging studies, either magnetic resonance imaging
(MRI) or computer tomography (CT), have value in the diagnosis
of encephalitis and myelitis, but are not affordable or available
to most patients living with HIV in Africa.
A diagnosis of CMV disease is rarely made antemortem in poorly
resourced African hospitals, as affordable diagnostics and treatment
for CMV have not been developed. Even in industrialised countries,
the diagnosis of CMV disease is often first made at autopsy [85],
in which the detection of classic owl‘s eye inclusions is indicative
of active CMV disease. However, autopsies are rarely performed
in Africa, as they require infrastructure and expertise that is
unavailable outside of major referral hospitals [72]. In addition,
there is also strong cultural opposition to mutilation of the
deceased [86]. A review of African autopsy studies from 2010
identified nine complete autopsy studies that included HIV-infected
cadavers, and found CMV disease in 4–18% of these [87]. A similar
review focusing on lung pathology gave a pooled prevalence of
7.5% (68/902) for CMV pneumonitis in HIV-infected adult
cadavers [72]. An autopsy study from Cote d’Ivoire (pre-ART)
found CMV disease to be the cause of death in 2% of patients
with HIV-1 compared with 18% of patients with HIV-2, possibly
because of longer survival with a low CD4 cell count in HIV-2-
infected individuals [88].
A study from South Africa among HIV-infected ART-naïve gold
miners found that mortality increased with higher CMV DNAemia
(>1000 copies/mL vs no viraemia) with an adjusted hazard ratio
of 3.7 [89]. An association between CMV DNAemia and risk of
dying was also found in a study from Tanzania among adults
initiating ART, where baseline CMV DNAemia (>200 copies/mL
in dried blood spots) was an independent risk factor for death
with an adjusted hazard ratio of 5.0 [42]. Among South African
patients in intensive care, CMV DNAemia (>1000 copies/mL) was
associated with a greater risk of mortality (hazard ratio: 3.5) [11].
CMV in non-HIV-infected immunosuppressed
adults
CMV may reactivate and cause severe disease after solid organ
and bone marrow transplantation [90,91]. Organ transplantation
is a rare procedure in most African countries, but in general CMV
represents a similar challenge to that inmost other countries, except
that CMV mismatch is less common due to high seroprevalence
in the population [90,91]. Patients with inflammatory bowel disease
(IBD) are also at risk of complications from CMV infection [92].
In a study from Egypt, evidence of CMV disease was found in 35%
of cases with steroid refractory colitis [93].This indicates that CMV
may play a role in at least certain populations with IBD in Africa
where this disease is diagnosed and treated. As healthcare services
in Africa improve, and more advanced treatment is offered, the
burden of CMV infection and disease is also likely to escalate.
CMV in Africa 139
Journal of Virus Eradication 2016; 2: 136–142 REVIEW
Diagnostic and therapeutic challenges
Globally, CMV DNA appears to be a biomarker of morbidity and
mortality in a range of patient groups [94], and this has also been
found in Africa. Uncontrolled data from South Africa indicate that
for severely ill patients ganciclovir therapy could be life-saving
[4,11], yet to date there have be no randomised controlled trials
of anti-CMV drugs in Africa. Of critical importance is the high cost
of ganciclovir and valganciclovir, and the perception that competing
priorities are more important. The development of new [95] or
cheaper generic CMV drugs and repurposing of available medicines
[96] are steps in the right direction, but treatment will only become
more available to low-income patient groups if trials are undertaken
and if they demonstrate sufficient impact. When designing
therapeutic trials for CMV, the method of diagnosis, and even the
definition of CMV disease, present several challenges. The
traditional gold standard of histopathological observation of ‘owl‘s
eye’ inclusions in diseased tissue requires invasive sampling (e.g.
pulmonary or gastrointestinal biopsy), and is an unlikely criterion
for use in clinical trials in Africa. Culture techniques have been
used to study CMV in Africa, from urine, saliva or respiratory
specimens [5,56], but more recent studies have used molecular
diagnostics. Large-scale investment in HIV and TB programmes,
along with other research activities, means that PCR platforms are
widely available at large teaching hospitals across Africa, the most
probable sites for anti-CMV drug trials. Standardised commercial
CMV PCR assays offer a quantitative measure of the CMV load,
facilitating reliable inter-site and inter-study comparisons. In South
Africa, intravenous ganciclovir is used at several centres to treat
infants with culture- or PCR-confirmed CMV pneumonitis [4–6],
but decisions are consultant-led and dosing informed by studies
from Western countries in transplant patients. Ganciclovir is
associated with a range of haematological adverse events,
especially neutropenia, and could be toxic in young infants with
fragile immune systems. Some researchers have proposed
diagnosing CMV in community-based studies, such as those
designed to investigate interactions between cCMV and early infant
CMV infections and developmental outcomes or vertical
transmission of HIV. Several groups have explored the use of dried
blood spots (DBS), which can be easily stored and transported
to research centres for CMV analysis [42,97,98].
Immunology
CMV is highly immunogenic and, more than the other human
herpesviruses, appears to be inextricably linked to the ageing of
the immune system. Establishment of chronic CMV infection leads
to a clonal expansion of differentiated CMV-specific CD8+ T cells,
which in older adults can account for up to 20% of the T cell
repertoire [99]. Due to the dominance of CMV as a target for
cell-mediated immunity, and the fact that primary CMV infection
is ubiquitous in African children, some researchers have sought
to study T cell responses to CMV, to gain insight into the
development of immunity in African infants that might inform on
vaccination strategies. Seminal studies from the Gambia used
tetramer staining to show that even in young infants, primary CMV
infection was followed by a rapid clonal expansion of differentiated
CMV-specific CD8+ T cells [100], which persisted for at least 2
years after primary infection [57]. Even the overall CD8+ T cell
population (which could have included T cells for other CMV
antigens) acquired the same differentiated phenotype after CMV
primary infection [100]. Conversely, CMV-specific CD4+ T cell
responses do not appear to be so important for the control of
CMV infection in the same infant population [57]. A study from
Malawi compared CD4+ and CD8+ T cell phenotypes between
HIV-1-negative Malawian and UK teenagers. All (n=59) Malawian
participants were CMV IgG seropositive, compared with 36%
(21/58) of UK teenagers. Malawian teenagers had a lower
proportion of naïve T cells and a higher proportion of memory T
cells compared with age-matched UK teenagers. Similarly, within
the UK teenagers, those who were CMV seropositive had reduced
proportions of naïve and increased memory T cells [101]. CMV
appears to be a driving component of this earlier ageing of the
immune system in African children, within the context of higher
exposure to a range of pathogens in high disease-burden settings.
A study that included adults and children from Tanzania replicated
some of these findings, and also showed that among adults,
increased IFN-γ and MIP-1β production by CMV-specific CD4+
T cells was linked independently to active TB infection [102]. There
are strong parallels between CMV and TB: They both establish
life-long latency, both reactivate upon immune suppression, both
cause acute disease in a broad range of tissues, and both are
associated with immune reconstitution inflammatory syndrome
(IRIS) in patients initiating ART [103]. A recent study in HIV-
infected adults from South Africa found that after ART, the recovery
of pathogen-specific T cells is relative to their memory phenotype
before treatment: for example, TB-specific T cells (which are
generally less differentiated) have a higher replenishment capacity
than those for CMV (which are generally more differentiated)
[104].
Conclusions
CMV is emerging as an important pathogen in African populations,
both as an acute cause of disease, and also as a more general
marker for poor outcomes, in children and immunosuppressed
patients. There is a need for greater implementation of diagnostic
tests and clinical trials for treatment of acute CMV disease in
patient groups such as HIV-infected or exposed children with CMV
pneumonia, and in HIV-infected adults with evidence of active
CMV infection or disease. Furthermore, for a range of clinical trials,
vaccination and immunology studies focused on African patients
with HIV or TB, investigators should consider the possible
confounding effects of CMV infection and incorporate viral load
testing into their protocols if appropriate.
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